-
2
-
-
80052763462
-
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi55-8
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 6
-
-
Eichenauer, D.A.1
Engert, A.2
Dreyling, M.3
-
3
-
-
0027404777
-
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
-
Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4
-
(1993)
Lancet
, vol.341
, pp. 1051-1054
-
-
Linch, D.C.1
Winfield, D.2
Goldstone, A.H.3
-
4
-
-
0037097044
-
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial
-
Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71
-
(2002)
Lancet
, vol.359
, pp. 2065-2071
-
-
Schmitz, N.1
Pfistner, B.2
Sextro, M.3
-
5
-
-
30144432586
-
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
-
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9
-
(2006)
Blood
, vol.107
, pp. 52-59
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
-
6
-
-
34548486030
-
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study
-
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52
-
(2007)
J Clin Oncol
, vol.25
, pp. 3746-3752
-
-
Gallamini, A.1
Hutchings, M.2
Rigacci, L.3
-
7
-
-
84863688504
-
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
-
Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7
-
(2012)
Nat Biotechnol
, vol.30
, pp. 631-637
-
-
Senter, P.D.1
Sievers, E.L.2
-
8
-
-
84863676500
-
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
-
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9
-
(2012)
J Clin Oncol
, vol.30
, pp. 2183-2189
-
-
Younes, A.1
Gopal, A.K.2
Smith, S.E.3
-
9
-
-
84865189087
-
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin Study Group experience
-
Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012;120:1470-2
-
(2012)
Blood
, vol.120
, pp. 1470-1472
-
-
Rothe, A.1
Sasse, S.2
Goergen, H.3
-
10
-
-
84875672985
-
Brentuximab vedotin in refractory CD30 + lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
-
Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30 + lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98:611-14
-
(2013)
Haematologica
, vol.98
, pp. 611-614
-
-
Gibb, A.1
Jones, C.2
Bloor, A.3
-
11
-
-
34548186696
-
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial
-
Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-502
-
(2007)
J Clin Oncol
, vol.25
, pp. 3495-3502
-
-
Engert, A.1
Franklin, J.2
Eich, H.T.3
-
12
-
-
35848959692
-
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
-
Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27
-
(2007)
N Engl J Med
, vol.357
, pp. 1916-1927
-
-
Ferme, C.1
Eghbali, H.2
Meerwaldt, J.H.3
-
13
-
-
77956646155
-
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
-
Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52
-
(2010)
N Engl J Med
, vol.363
, pp. 640-652
-
-
Engert, A.1
Plutschow, A.2
Eich, H.T.3
-
14
-
-
78149436503
-
Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: Results of the second interim analysis of the GHSG HD13 trial
-
Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica 2010;95(Suppl 2):A1146
-
(2010)
Haematologica
, vol.95
, Issue.SUPPL. 2
-
-
Borchmann, P.1
Diehl, V.2
Goergen, H.3
-
15
-
-
84888811392
-
Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma
-
Andre MP, Reman O, Federico M, et al. Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. ASH Annual Meeting Abstracts 2012;120:549
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 549
-
-
Andre, M.P.1
Reman, O.2
Federico, M.3
-
16
-
-
84888785814
-
Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 Cycles ABVD. Results of the UK NCRI RAPID trial
-
Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 Cycles ABVD. Results of the UK NCRI RAPID trial. ASH Annual Meeting Abstracts 2012;120:547
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 547
-
-
Radford, J.1
Barrington, S.2
Counsell, N.3
-
17
-
-
77957945999
-
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial
-
Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-206
-
(2010)
J Clin Oncol
, vol.28
, pp. 4199-4206
-
-
Eich, H.T.1
Diehl, V.2
Gorgen, H.3
-
18
-
-
33744829443
-
Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial
-
Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. ASH Annual Meeting Abstracts 2005;106:813
-
(2005)
ASH Annual Meeting Abstracts
, vol.106
, pp. 813
-
-
Ferme, C.1
Divine, M.2
Vranovsky, A.3
-
19
-
-
84860626866
-
Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial
-
von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-13
-
(2012)
J Clin Oncol
, vol.30
, pp. 907-913
-
-
Von Tresckow, B.1
Plutschow, A.2
Fuchs, M.3
-
20
-
-
84863011979
-
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma
-
Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399-408
-
(2012)
N Engl J Med
, vol.366
, pp. 399-408
-
-
Meyer, R.M.1
Gospodarowicz, M.K.2
Connors, J.M.3
-
21
-
-
0026439199
-
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
-
Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84
-
(1992)
N Engl J Med
, vol.327
, pp. 1478-1484
-
-
Canellos, G.P.1
Anderson, J.R.2
Propert, K.J.3
-
22
-
-
0037007678
-
Long-term follow-up of Hodgkin's disease trial
-
Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-18
-
(2002)
N Engl J Med
, vol.346
, pp. 1417-1418
-
-
Canellos, G.P.1
Niedzwiecki, D.2
-
24
-
-
0037567428
-
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
-
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95
-
(2003)
N Engl J Med
, vol.348
, pp. 2386-2395
-
-
Diehl, V.1
Franklin, J.2
Pfreundschuh, M.3
-
25
-
-
71049118685
-
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
-
Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
-
(2009)
J Clin Oncol
, vol.27
, pp. 4548-4554
-
-
Engert, A.1
Diehl, V.2
Franklin, J.3
-
26
-
-
19944428790
-
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
-
Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-31
-
(2005)
Ann Oncol
, vol.16
, pp. 124-131
-
-
Ballova, V.1
Ruffer, J.U.2
Haverkamp, H.3
-
27
-
-
84884822211
-
Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: An analysis of the German Hodgkin study group
-
Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin study group. J Clin Oncol 2013;31:2819-24
-
(2013)
J Clin Oncol
, vol.31
, pp. 2819-2824
-
-
Wongso, D.1
Fuchs, M.2
Plutschow, A.3
-
28
-
-
84860833364
-
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial
-
Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
-
(2012)
Lancet
, vol.379
, pp. 1791-1799
-
-
Engert, A.1
Haverkamp, H.2
Kobe, C.3
-
29
-
-
59949089090
-
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
-
Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11
-
(2009)
J Clin Oncol
, vol.27
, pp. 805-811
-
-
Federico, M.1
Luminari, S.2
Iannitto, E.3
-
30
-
-
79960583495
-
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
-
Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12
-
(2011)
N Engl J Med
, vol.365
, pp. 203-212
-
-
Viviani, S.1
Zinzani, P.L.2
Rambaldi, A.3
-
31
-
-
84878399823
-
ABVD (8 cycles) versus BEACOPP (4 escalated cycles → 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial
-
Carde PP, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles → 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): first results of EORTC 20012 Intergroup randomized phase III clinical trial. ASCO Meeting Abstracts 2012;30:8002
-
(2012)
ASCO Meeting Abstracts
, vol.30
, pp. 8002
-
-
Carde, P.P.1
Karrasch, M.2
Fortpied, C.3
-
32
-
-
84883050177
-
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: A systematic review and network meta-analysis
-
Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14:943-52
-
(2013)
Lancet Oncol
, vol.14
, pp. 943-952
-
-
Skoetz, N.1
Trelle, S.2
Rancea, M.3
-
33
-
-
84926296446
-
Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkińs lymphoma patients with positive positron emission tomography after two courses of chemotherapy: Preliminary results of the IIL HD-0801 study
-
Abstract 016
-
Zinzani PL, Bonfichi M, Rossi G, et al. Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkińs lymphoma patients with positive positron emission tomography after two courses of chemotherapy: preliminary results of the IIL HD-0801 study. Haematologica 2013;98:Abstract 016
-
(2013)
Haematologica
, pp. 98
-
-
Zinzani, P.L.1
Bonfichi, M.2
Rossi, G.3
-
34
-
-
84892146425
-
Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL/FIL HD0607 clinical trial
-
Gallamini A, Rossi A, Patti C, et al. Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL/FIL HD0607 clinical trial. ASH Annual Meeting Abstracts 2012;120:550
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 550
-
-
Gallamini, A.1
Rossi, A.2
Patti, C.3
-
35
-
-
84888138217
-
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study
-
Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
-
(2013)
Lancet Oncol
, vol.14
, pp. 1348-1356
-
-
Younes, A.1
Connors, J.M.2
Park, S.I.3
-
36
-
-
84900794661
-
Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: Interim results of a randomized phase II study
-
Borchmann P, Eichenauer DA, Plütschow A, et al. Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Blood 2013;122:4344
-
(2013)
Blood
, vol.122
, pp. 4344
-
-
Borchmann, P.1
Eichenauer, D.A.2
Plütschow, A.3
-
37
-
-
79951890275
-
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
-
Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074-80
-
(2010)
J Clin Oncol
, vol.28
, pp. 5074-5080
-
-
Josting, A.1
Muller, H.2
Borchmann, P.3
-
38
-
-
33846925670
-
Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma
-
Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92:35-41
-
(2007)
Haematologica
, vol.92
, pp. 35-41
-
-
Santoro, A.1
Magagnoli, M.2
Spina, M.3
-
39
-
-
0035253827
-
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
-
Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23
-
(2001)
Blood
, vol.97
, pp. 616-623
-
-
Moskowitz, C.H.1
Nimer, S.D.2
Zelenetz, A.D.3
-
40
-
-
84898410834
-
A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: Final results after early trial discontinuation
-
von Tresckow B, Skotnicki A, Lisukov I, et al. A phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Blood 2013;122:4648
-
(2013)
Blood
, vol.122
, pp. 4648
-
-
Von Tresckow, B.1
Skotnicki, A.2
Lisukov, I.3
-
41
-
-
24644460669
-
Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group
-
Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005;23:5052-60
-
(2005)
J Clin Oncol
, vol.23
, pp. 5052-5060
-
-
Engert, A.1
Ballova, V.2
Haverkamp, H.3
-
42
-
-
84876515821
-
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials
-
Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:1522-9
-
(2013)
J Clin Oncol
, vol.31
, pp. 1522-1529
-
-
Boll, B.1
Gorgen, H.2
Fuchs, M.3
-
43
-
-
83455220148
-
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
-
Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011;118:6292-8
-
(2011)
Blood
, vol.118
, pp. 6292-6298
-
-
Boll, B.1
Bredenfeld, H.2
Gorgen, H.3
-
44
-
-
84862734110
-
Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: The SHIELD study
-
Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012;119:6005-15
-
(2012)
Blood
, vol.119
, pp. 6005-6015
-
-
Proctor, S.J.1
Wilkinson, J.2
Jones, G.3
-
45
-
-
33947612578
-
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
-
Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007;48:570-6
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 570-576
-
-
Kolstad, A.1
Nome, O.2
Delabie, J.3
-
46
-
-
84900831378
-
German Hodgkin study group phase i trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients
-
Boll B, Plütschow A, Fuchs M, et al. German Hodgkin study group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood 2013;122:3054
-
(2013)
Blood
, vol.122
, pp. 3054
-
-
Boll, B.1
Plütschow, A.2
Fuchs, M.3
-
47
-
-
84894356294
-
Relapsed Hodgkin lymphoma in older patients: A comprehensive analysis from the German Hodgkin Study Group
-
Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2013;31:4431-7
-
(2013)
J Clin Oncol
, vol.31
, pp. 4431-4437
-
-
Boll, B.1
Goergen, H.2
Arndt, N.3
-
48
-
-
39049195371
-
Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma
-
Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006;266-72
-
(2006)
Hematology Am Soc Hematol Educ Program
, pp. 266-272
-
-
Nogova, L.1
Rudiger, T.2
Engert, A.3
-
49
-
-
84861813756
-
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
-
Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:589-97
-
(2012)
J Natl Compr Canc Netw
, vol.10
, pp. 589-597
-
-
Hoppe, R.T.1
Advani, R.H.2
Ai, W.Z.3
-
50
-
-
27144479926
-
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)
-
Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005;16:1683-7
-
(2005)
Ann Oncol
, vol.16
, pp. 1683-1687
-
-
Nogova, L.1
Reineke, T.2
Eich, H.T.3
-
51
-
-
73949125030
-
Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up
-
Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136-41
-
(2010)
J Clin Oncol
, vol.28
, pp. 136-141
-
-
Chen, R.C.1
Chin, M.S.2
Ng, A.K.3
-
52
-
-
80054835220
-
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
-
Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-5
-
(2011)
Blood
, vol.118
, pp. 4363-4365
-
-
Eichenauer, D.A.1
Fuchs, M.2
Pluetschow, A.3
-
53
-
-
80055074730
-
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
-
Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585-90
-
(2011)
Blood
, vol.118
, pp. 4585-4590
-
-
Savage, K.J.1
Skinnider, B.2
Al-Mansour, M.3
-
54
-
-
38649125204
-
Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group
-
Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-9
-
(2008)
J Clin Oncol
, vol.26
, pp. 434-439
-
-
Nogova, L.1
Reineke, T.2
Brillant, C.3
-
55
-
-
84873064941
-
Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP
-
Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts 2010;116:2812
-
(2010)
ASH Annual Meeting Abstracts
, vol.116
, pp. 2812
-
-
Fanale, M.A.1
Lai, C.-M.2
McLaughlin, P.3
-
56
-
-
38049162295
-
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
-
Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-11
-
(2008)
Blood
, vol.111
, pp. 109-111
-
-
Schulz, H.1
Rehwald, U.2
Morschhauser, F.3
-
57
-
-
84877912785
-
High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
-
Karuturi M, Hosing C, Fanale M, et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant 2013;19:991-4
-
(2013)
Biol Blood Marrow Transplant
, vol.19
, pp. 991-994
-
-
Karuturi, M.1
Hosing, C.2
Fanale, M.3
-
58
-
-
4143080389
-
Solid tumors in patients treated for Hodgkin's disease: A report from the German Hodgkin Lymphoma Study Group
-
Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004;15:1079-85
-
(2004)
Ann Oncol
, vol.15
, pp. 1079-1085
-
-
Behringer, K.1
Josting, A.2
Schiller, P.3
-
59
-
-
84897530655
-
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group
-
Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123:1658-64
-
(2014)
Blood
, vol.123
, pp. 1658-1664
-
-
Eichenauer, D.A.1
Thielen, I.2
Haverkamp, H.3
-
60
-
-
80755127111
-
Second cancer risk after chemotherapy for Hodgkin's lymphoma: A collaborative British cohort study
-
Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096-104
-
(2011)
J Clin Oncol
, vol.29
, pp. 4096-4104
-
-
Swerdlow, A.J.1
Higgins, C.D.2
Smith, P.3
-
62
-
-
67649646579
-
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma
-
De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-37
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 928-937
-
-
De Bruin, M.L.1
Dorresteijn, L.D.2
Van'T Veer, M.B.3
-
63
-
-
58049219093
-
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group
-
Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980-7
-
(2008)
J Clin Oncol
, vol.26
, pp. 5980-5987
-
-
Morschhauser, F.1
Brice, P.2
Ferme, C.3
-
64
-
-
84891073765
-
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG)
-
Hartmann S, Eichenauer DA, Plutschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013;122:4246-52
-
(2013)
Blood
, vol.122
, pp. 4246-4252
-
-
Hartmann, S.1
Eichenauer, D.A.2
Plutschow, A.3
-
65
-
-
84900823372
-
Nodular lymphocyte predominant Hodgkin's lymphoma-evaluation of a scoring system to predict recurrences
-
Abstract 145
-
Panjwani P, Epari S, Sengar M, et al. Nodular lymphocyte predominant Hodgkin's lymphoma-evaluation of a scoring system to predict recurrences. Haematologica 2013;98:Abstract 145
-
(2013)
Haematologica
, pp. 98
-
-
Panjwani, P.1
Epari, S.2
Sengar, M.3
-
66
-
-
33749262442
-
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
-
Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006;77:387-94
-
(2006)
Eur J Haematol
, vol.77
, pp. 387-394
-
-
Visco, C.1
Nadali, G.2
Vassilakopoulos, T.P.3
-
67
-
-
84872928596
-
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
-
Sauer M, Plutschow A, Jachimowicz RD, et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013;88:113-15
-
(2013)
Am J Hematol
, vol.88
, pp. 113-115
-
-
Sauer, M.1
Plutschow, A.2
Jachimowicz, R.D.3
-
68
-
-
84879750415
-
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial
-
Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 2013;121:3547-53
-
(2013)
Blood
, vol.121
, pp. 3547-3553
-
-
Kanakry, J.A.1
Li, H.2
Gellert, L.L.3
|